ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Malignant cell-secreted chemokines drive colorectal cancer progression through endothelial cell activation.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cell interactions within the tumor microenvironment (TME) fundamentally reshape the immune landscape, influencing clinical phenotypes in colorectal cancer (CRC). In this study, we integrated single-cell RNA sequencing (scRNA-seq), inference of copy number variations (inferCNV), and non-negative matrix factorization (NMF) to decipher the TME dynamics in 26 CRC patients, stratified by their T stages (T2, T3, T4a). Malignant cells, characterized via inferCNV, exhibited specific immune-related patterns in the most advanced T4a stage, identified through NMF. Genes involved in guiding chemotaxis showed either increasing or decreasing activity as the tumor stage progressed. Four candidate genes (CXCL1, CXCL2, CXCL3, and GDF15) were prioritized, with their elevated expression levels correlating with tumor invasion. Further analysis pinpointed C-X-C motif chemokine ligand 2 (CXCL2) as a critical factor. CXCL2 serves as a canonical ligand for atypical chemokine receptor 1 (ACKR1), and their interaction is vital for immune cells to move into inflammatory sites. In T4a CRC, CXCL2 derived from malignant cells acts on ACKR1 enriched at junctions of endothelial cells (ECs). Knockdown of either CXCL2 in LoVo cells or ACKR1 in human umbilical vein endothelial cells (HUVECs) significantly inhibited cancer cell migration toward ECs. Collectively, these findings indicate that as CRC advances, increased secretion of CXCL2 from malignant cells stimulates ACKR1 on ECs, thereby promoting tumor invasion and metastasis. This study provides a framework for stage-specific interventions, particularly for locally advanced CRC, by disrupting ACKR1 on ECs within TME to impede metastasis and improve clinical outcomes.
Indexed as
Identifiers
41557142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.